Dutch Injunction Constrains Keytruda SC Across Eight Markets

Company Halozyme; Merck (MSD) Event Type Patent injunction (source-gap catch-up of 7 October ruling) Modality Subcutaneous biologic delivery (hyaluronidase-based technology) Asset Keytruda SC (subcutaneous pembrolizumab) Target PD-1 (pembrolizumab); MDASE patent EP 2,797,622 Disease Area Oncology (multiple cancers) Summary A specialized Dutch court found that Merck’s…